Abstract

Adverse cutaneous drug reaction (ACDR) is a challenging condition for clinician, especially in determining the etiologic drug. Identification of etiologic drug become more difficult when the patient consume multiple drugs at once. As cellular immunity response is the main mechanism underlying exanthematous eruption, the most common type of ACDR, patch test rise as the reliable diagnostic modality to find the etiologic drug as this test represent the same mechanism as ACDR. In this paper, we reported commercial drug patch test application testing Griseofulvin, Amoxicillin, Ibuprofen, Aspirin and Clindamycin in 37 years old woman with history of drug induced-exfoliative dermatitis six months ago. Patch test technique involves patient preparations, test drug formulation, test drug patching and evaluation on day 2, 4 and 7. Before doing patch test, patient must not take any corticosteroid or immunosuppressant drug within one month ahead. The suspected drug consist of Griseofulvin, Ibuprofen and Clindamycin. Amoxicillin was chosen as the cross reacted drug for Griseofulvin while Aspirin was chosen as the cross reacted drug of Ibuprofen. All tested drugs were formulated as homogenous powder with 10% concentration and mixed with white paraffin. The formulated drug was patched to patient’s back using 7 mm diameter finn chamber. The evaluation result showed positive reaction towards Griseofulvin and weak positive reaction towards Amoxicillin

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.